Galapagos and Merck & Co., Inc. agree to end strategic alliances
Merck pays Galapagos €12 M for results delivered in 2010
Including the payment of €12 million, Galapagos will have received a total of €20.9 million in upfront and milestone payments derived from the alliances. Galapagos has regained worldwide rights to the targets discovered and assays developed from the collaboration.
"In the alliances with Merck, we have discovered promising targets and developed target discovery assays for diseases with considerable unmet medical needs. Galapagos now owns these valuable assets which can form the basis for future alliances," said Onno van de Stolpe, CEO of Galapagos. "The work delivered to Merck last year also made a strong contribution to Galapagos' financial results in 2010."
"Changes in our early discovery strategy have required us to make some challenging decisions," said Kathleen Metters, Senior Vice President, External Discovery and Preclinical Sciences, at Merck. "We look forward to investigating alternate opportunities to collaborate with Galapagos in the future."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.